Harrow Inc is a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of innovative ophthalmic solutions. The company aims to improve patient outcomes through its portfolio of prescription eye medications, which are designed to address various ocular conditions and diseases. Harrow combines its expertise in drug formulation and compounding with a commitment to enhancing the quality of life for patients suffering from eye-related issues, positioning itself as a leader within the ophthalmic pharmaceutical sector. Through strategic partnerships and a dedication to research and development, Harrow strives to expand its offerings and address unmet medical needs in the eye care market. Read More
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Harrow Inc (HROW) is a high-growth ophthalmic pharma stock with strong revenue expansion and a bullish technical breakout setup, signaling potential upward momentum.
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
